Shares of PepGen, Inc. (NASDAQ:PEPG – Get Free Report) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $11.50.
Several research analysts have recently commented on PEPG shares. HC Wainwright reissued a “buy” rating on shares of PepGen in a report on Thursday, May 21st. Wedbush lowered their target price on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. Craig Hallum initiated coverage on shares of PepGen in a report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, Weiss Ratings cut shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd.
Get Our Latest Stock Report on PepGen
Hedge Funds Weigh In On PepGen
PepGen Stock Performance
PepGen stock opened at $2.12 on Wednesday. PepGen has a fifty-two week low of $1.01 and a fifty-two week high of $7.80. The stock has a market cap of $146.64 million, a P/E ratio of -1.21 and a beta of 1.88. The firm’s fifty day moving average price is $1.74 and its 200-day moving average price is $3.49.
PepGen (NASDAQ:PEPG – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. Sell-side analysts predict that PepGen will post -1.2 earnings per share for the current year.
PepGen Company Profile
PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.
The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).
Further Reading
- Five stocks we like better than PepGen
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.
